Promoter hypermethylation identifies progression risk in bladder cancer.

Promoter hypermethylation identifies progression risk in bladder cancer.

PURPOSE: New methods to accurately predict an individual tumor behavior are urgently required to improve the treatment of cancer. We previously found that promoter hypermethylation can be an accurate predictor of bladder cancer progression, but it is not cancer specific. Here, we investigate a pane...

Descripció completa

Dades bibliogràfiques
Autors principals:	Yates, DR, Rehman, I, Abbod, M, Meuth, M, Cross, S, Linkens, D, Hamdy, F, Catto, J
Format:	Journal article
Idioma:	English
Publicat:	2007

Ítems similars

A gene promoter hypermethylation panel to detect transitional cell carcinoma of the bladder
per: Yates, DR, et al.
Publicat: (2006)

Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.
per: Rouprêt, M, et al.
Publicat: (2008)

Promoter hypermethylation in circulating blood cells identifies prostate cancer progression
per: Roupret, M, et al.
Publicat: (2008)

Development of a prognostic marker panel in bladder cancer using aberrant promoter methylation
per: Catto, J, et al.
Publicat: (2007)

Comparative study of intelligent models for the prediction of bladder cancer progression.
per: Abbod, M, et al.
Publicat: (2006)

Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression.
per: Catto, J, et al.
Publicat: (2006)

Comparing gene promoter methylation frequencies in urine from patients with bladder cancer with urine from non-cancerous young and elderly control patients
per: Yates, DR, et al.
Publicat: (2005)

Artificial intelligence for the prediction bladder cancer
per: Abbod, M, et al.
Publicat: (2004)

Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
per: Catto, J, et al.
Publicat: (2005)

Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls.
per: Yates, DR, et al.
Publicat: (2006)

Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer.
per: Leiblich, A, et al.
Publicat: (2006)

Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer
per: Catto, J, et al.
Publicat: (2006)

Improving gene array analysis: The application of artificial intelligence identifies novel biomarkers of non invasive papillary bladder cancer progression
per: Wild, P, et al.
Publicat: (2007)

Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
per: Catto, J, et al.
Publicat: (2009)

The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression.
per: Catto, J, et al.
Publicat: (2010)

Predictive modeling in cancer: where systems biology meets the stock market.
per: Abbod, M, et al.
Publicat: (2009)

Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks.
per: Catto, J, et al.
Publicat: (2003)

Application of artificial intelligence to the management of urological cancer
per: Abbod, MF, et al.
Publicat: (2007)

Artificial intelligence re-analysis of gene array data identifies novel markers of urothelial cancer progression
per: Catto, J, et al.
Publicat: (2007)

Aberrant promoter methylation in pre-malignant and invasive tumours of the urinary bladder
per: Yates, D, et al.
Publicat: (2005)

Artificial intelligence technique for gene expression profiling of urinary bladder cancer
per: Abbod, M, et al.
Publicat: (2006)

Proteomics and immunohistochemistry identify loss of nucleophosmin (B23) expression in bladder transitional cell carcinomas
per: Ahmad, M, et al.
Publicat: (2003)

Artificial intelligence technique for gene expression profiling of urinary bladder cancer
per: Abbod, M, et al.
Publicat: (2006)

Artificial intelligence and bladder cancer arrays.
per: Wild, P, et al.
Publicat: (2007)

Genetic instability and transitional cell carcinoma of the bladder.
per: Catto, J, et al.
Publicat: (2004)

Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer.
per: Dudziec, E, et al.
Publicat: (2011)

PER3 promoter hypermethylation correlates to the progression of pan-cancer
per: Yaoxu Li, et al.
Publicat: (2024-10-01)

Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability.
per: Catto, J, et al.
Publicat: (2003)

Itraq-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression
per: Rehman, I, et al.
Publicat: (2008)

iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression.
per: Glen, A, et al.
Publicat: (2008)

Inactivation of the hypermethylated in cancer 1 tumour suppressor – not just a question of promoter hypermethylation?
per: M Jenal, et al.
Publicat: (2010-10-01)

Role of hypermethylated-lncRNAs in the prognosis of bladder cancer patients
per: Junhua Luo, et al.
Publicat: (2021-10-01)

Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
per: Dhawan, D, et al.
Publicat: (2006)

Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
per: Rehman, I, et al.
Publicat: (2004)

Hypermethylation at 45S rDNA promoter in cancers.
per: Trang Thi Quynh Tran, et al.
Publicat: (2025-01-01)

Hypermethylation at 45S rDNA promoter in cancers
per: Trang Thi Quynh Tran, et al.
Publicat: (2025-01-01)

Epigenetic changes in urothelial cancer: A feature of the invasive phenotype and a novel therapeutic target
per: Catto, J, et al.
Publicat: (2006)

Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression
per: Mansukhani Mahesh, et al.
Publicat: (2006-05-01)

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.
per: Catto, J, et al.
Publicat: (2010)

FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
per: van Oers, J, et al.
Publicat: (2009)